Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMNIVORE Study in Advanced Renal Cell Carcinoma
NCT03203473Phase 2Active, not recruiting
- Start
- Oct 2017
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in renal cell carcinoma (RCC). Started Oct 2017; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03203473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03203473.